Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population

Journal of Immunology

Volumn 167, Issue 5, 2001, Pages 2569-2576

  Karnbach, C ^a   Daws, M R ^a   Niemi, E C ^a   Nakamura, M C ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CD1 ANTIGEN; CYCLOPHOSPHAMIDE; RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; IMMUNOTHERAPY; LIVER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SARCOMA; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR REGRESSION;

EID: 0035451072     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.5.2569     Document Type: Article

References (45)

1. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
2. Recombinant IL-12 administration induces tumor regression in association with IFN-Γ production
3. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells
4. + αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis
5. IL-12 induces T helper 1-directed antitumor response
6. Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12
7. Longlasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA
8. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12
9. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions
10. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12
11. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
12. Requirement for Vα14 NK T cells in IL-12-mediated rejection of tumors
13. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12
14. + αβ T cells with intermediate TCR induced in the liver of mice by IL-12
15. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12
16. The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent
17. + T cells in IL-12-induced immune responses in vivo
18. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models
19. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice
20. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18
21. Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine
22. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy
23. Immunosuppressive drugs: The first 50 years and a glance forward
24. Relative susceptibilities of T cell subsets involved in delayed-type hypersensitivity to sheep red blood cells to the in vitro action of 4-hydroperoxycyclophosphamide
25. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide
26. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant turnout: Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden
27. Transforming growth factor β1 (TGF-β1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant
28. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells
29. Molecular cloning of gp42, a cell-surface molecule that is selectively induced on rat natural killer cells by interleukin 2: Glycolipid membrane anchoring and capacity for transmembrane signaling
30. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1: Reduction in host defense against malignancy without loss of cellular or humoral immunity
31. NKT cells are phenotypically and functionally diverse
32. + T cell development and early IL-4 production in CD1-deficient mice
33. Rapid death and regeneration of NKT cells in anti-CD3ε- or IL-12-treated mice: A major role for bone marrow in NKT cell homeostasis
34. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells
35. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers
36. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
37. Differential tumor surveillance by natural killer (NK) and NKT cells
38. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector
39. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively
40. Signalling through NK1.1 triggers NK cells to die but induces NK T cells to produce interleukin-4
41. + T cells
42. + T cells rapidly acquire NK1.1 and NK cell-associated molecules upon stimulation in vitro and in vivo
43. + T cells lose NK1.1 expression upon in vitro activation
44. +NKT cells to the liver
45. Immune suppression and skin cancer development: Regulation by NKT cells